Andalib Ali, Chetrit Michael, Eberg Masha, Filion Kristian B, Thériault-Lauzier Pascal, Lange Ruediger, Buithieu Jean, Martucci Giuseppe, Eisenberg Mark, Bolling Steven F, Piazza Nicolo
Department of Cardiology, McGill University Health Centre, Montreal, Quebec, Canada.
Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.
J Heart Valve Dis. 2016 Nov;25(6):696-707.
The surgical correction of functional mitral regurgitation (MR) remains challenging and controversial. The study aim was to systematically review the outcomes of surgical mitral valve repair (MVRpr) and mitral valve replacement (MVR) in patients with significant functional MR and left ventricular (LV) dysfunction.
A meta-analysis was performed of published data acquired from patients with moderate to severe functional MR and LV ejection fraction (LVEF) <40% who underwent surgical MVRpr or MVR. The data were meta-analyzed across studies using Bayesian hierarchical models when feasible.
The search yielded 36 observational studies. The pooled proportion of operative mortality following MVRpr was 5% (33 studies; 2,231 patients; 95% credible interval (CrI) 4-7%), while that following MVR was 10% (10 studies; 389 patients; 95% CrI 5-18%). For patients undergoing MVRpr, pooled proportions of postoperative cerebrovascular accidents and renal failure were 2% (11 studies; 750 patients; 95% CrI 1-3%) and 9% (11 studies; 756 patients; 95% CrI 5-16%), respectively. The five-year actuarial survival rates following MVRpr across 12 studies ranged from 47% to 78% (median 66%).
In selected patients with significant functional MR and LV dysfunction, surgical MVRpr and MVR can be performed with acceptable intermediate operative mortality risks.
功能性二尖瓣反流(MR)的外科矫治仍然具有挑战性且存在争议。本研究的目的是系统评价重度功能性MR和左心室(LV)功能障碍患者行二尖瓣修复术(MVRpr)和二尖瓣置换术(MVR)的疗效。
对已发表的中度至重度功能性MR且左心室射血分数(LVEF)<40%并接受外科MVRpr或MVR患者的数据进行荟萃分析。可行时,采用贝叶斯分层模型对各项研究的数据进行荟萃分析。
检索到36项观察性研究。MVRpr术后的汇总手术死亡率为5%(33项研究;2231例患者;95%可信区间(CrI)4 - 7%),而MVR术后为10%(10项研究;389例患者;95% CrI 5 - 18%)。对于接受MVRpr的患者,术后脑血管意外和肾衰竭的汇总比例分别为2%(11项研究;750例患者;95% CrI 1 - 3%)和9%(11项研究;756例患者;95% CrI 5 - 16%)。12项研究中MVRpr术后的五年精算生存率在47%至78%之间(中位数为66%)。
在特定的重度功能性MR和LV功能障碍患者中,外科MVRpr和MVR可以在可接受的中期手术死亡风险下进行。